Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Combination study of VB-111 with a checkpoint inhibitor in patients with non-small cell lung cancer

Next Previous
X
Search
Trial Profile

Combination study of VB-111 with a checkpoint inhibitor in patients with non-small cell lung cancer

Status: Planning
Phase of Trial: Phase I/II

Latest Information Update: 26 Jun 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ofranergene obadenovec (Primary)
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions

    • Most Recent Events

    • 27 Dec 2017 According to a VBL Therapeutics media release, this trial is expected to begin in the first quarter of 2018.
    • 14 Aug 2017 Planned initiation date changed from 1 Dec 2017 to 1 Jan 2018, according to a VBL Therapeutics media release.
    • 27 Jun 2017 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top